{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:53:57Z","timestamp":1792068837612,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bmcl.2026.130791","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:28:33Z","timestamp":1790954913000},"page":"130791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and preliminary in vitro screening of novel tolmetin hydrazones against colon cancer"],"prefix":"10.1016","volume":"142","author":[{"given":"Ecem","family":"G\u00f6ko\u011flan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130rem","family":"Atlihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimet Sema","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Mega Tiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015e. G\u00fcniz","family":"K\u00fc\u00e7\u00fckg\u00fczel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130791_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmcl.2026.130791_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032314","article-title":"Predictive biomarkers of colon cancer immunotherapy: present and future","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2026.130791_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2006.01.003","article-title":"Cyclooxygenase-2 as a target for anticancer drug development","volume":"59","author":"M\u00e9ric","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bmcl.2026.130791_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bmcl.2026.130791_bb0025","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.bmcl.2026.130791_bb0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jjco\/28.7.421","article-title":"Increased expression of cyclooxygenase-2 to \u22121 in human colorectal cancers and adenomas, but not in hyperplastic polyps","volume":"28","author":"Maekawa","year":"1998","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.bmcl.2026.130791_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10787-009-8049-8","article-title":"Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung","volume":"17","author":"Harris","year":"2009","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bmcl.2026.130791_bb0040","article-title":"Role of nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention and cancer promotion","volume":"2019","author":"Wong","year":"2019","journal-title":"Adv Pharmacol Pharm Sci"},{"key":"10.1016\/j.bmcl.2026.130791_bb0045","first-page":"176","article-title":"Cyclooxygenase 2 inhibitors and colon cancer","volume":"4","author":"Gonzalez-Angulo","year":"2002","journal-title":"Ochsner J"},{"key":"10.1016\/j.bmcl.2026.130791_bb0050","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ardp.201500178","article-title":"Synthesis of tolmetin hydrazide-hydrazones and discovery of a potent apoptosis inducer in colon cancer cells","volume":"348","author":"K\u00fc\u00e7\u00fckg\u00fczel","year":"2015","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bmcl.2026.130791_bb0055","doi-asserted-by":"crossref","first-page":"18567","DOI":"10.1073\/pnas.0509316102","article-title":"Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2026.130791_bb0060","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0959-8049(98)00045-8","article-title":"Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)","volume":"34","author":"Duffy","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmcl.2026.130791_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.51847\/WWPYUT4Nig","article-title":"Studying the efficacy of tolmetin radiosensitizing effect in radiotherapy treatment on human clonal cancer cells","volume":"13","author":"Kwatra","year":"2024","journal-title":"Int J Pharm Res Allied Sci"},{"key":"10.1016\/j.bmcl.2026.130791_bb0070","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/14756366.2021.1901089","article-title":"Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers","volume":"36","author":"Kassab","year":"2021","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmcl.2026.130791_bb0075","first-page":"259","article-title":"Synthesis and anticancer activity of tolmetin thiosemicarbazides","volume":"19","author":"Dada\u015f","year":"2015","journal-title":"J Res Pharm"},{"key":"10.1016\/j.bmcl.2026.130791_bb0080","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/12081910","article-title":"Biological activities of hydrazone derivatives","volume":"12","author":"Rollas","year":"2007","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130791_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138012","article-title":"Hydrazide-hydrazone\/hydrazone as enabling linkers in anti-cancer drug discovery: a comprehensive review","volume":"1307","author":"Murugappan","year":"2024","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmcl.2026.130791_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116097","article-title":"Design and synthesis of novel (S)-naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro\/in vivo breast cancer models","volume":"37","author":"Han","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2026.130791_bb0095","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ardp.201200449","article-title":"Synthesis, cytotoxicity and pro-apoptosis activity of etodolac hydrazide derivatives as anticancer agents","volume":"346","author":"\u00c7\u0131kla","year":"2013","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bmcl.2026.130791_bb0100","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.bmcl.2014.09.018","article-title":"Rational design, synthesis and anti-proliferative evaluation of novel benzosuberone tethered with hydrazide\u2013hydrazones","volume":"24","author":"Yadagiri","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130791_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139240","article-title":"Imidazole-based hydrazones as potent anti-colon cancer agents: design, synthesis, biological evaluation and computational studies","volume":"1318","author":"Tapera","year":"2024","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmcl.2026.130791_bb0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejmech.2015.10.041","article-title":"Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors","volume":"108","author":"\u015eenkarde\u015f","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130791_bb0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.17344\/acsi.2025.9452","article-title":"Novel hydrazide-hydrazone derivatives containing flurbiprofen 1,2,4-triazole as anticancer agents: design, synthesis and biological evaluation","volume":"73","author":"G\u00f6ko\u011flan","year":"2026","journal-title":"Acta Chim Slov"},{"key":"10.1016\/j.bmcl.2026.130791_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26164908","article-title":"Synthesis of novel N-acylhydrazones and their C-N\/N-N bond conformational characterization by NMR spectroscopy","volume":"26","author":"Munir","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130791_bb0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molstruc.2005.11.018","article-title":"NMR study of conformation and isomerization of aryl- and heteroarylaldehyde 4-tert-butylphenoxyacetylhydrazones","volume":"788","author":"Syakaev","year":"2006","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmcl.2026.130791_bb0130","doi-asserted-by":"crossref","first-page":"8719","DOI":"10.3390\/molecules27248719","article-title":"Acylhydrazones and their biological activity: a review","volume":"27","author":"Socea","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130791_bb0135","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1016\/S0040-4020(01)87332-4","article-title":"Conformational behaviour and E\/Z isomerization of N-acyl and N-aroylhydrazones","volume":"42","author":"Palla","year":"1986","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmcl.2026.130791_bb0140","first-page":"217","article-title":"Antitumor activity and mechanism study of riluzole and its derivatives","volume":"19","author":"Wu","year":"2020","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.bmcl.2026.130791_bb0145","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.131336.3","article-title":"Assessing the cytotoxicity of phenolic and terpene fractions extracted from Iraqi Prunus arabica against AMJ13 and SK-GT-4 human cancer cell lines","volume":"12","author":"Mahmood","year":"2024","journal-title":"F1000Res"},{"key":"10.1016\/j.bmcl.2026.130791_bb0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1076029616665924","article-title":"Mitochondrial inner membrane depolarization as a marker of platelet apoptosis","volume":"23","author":"Gyulkhandanyan","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.bmcl.2026.130791_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108850","article-title":"Investigation of novel nimesulide derivatives against breast cancer","volume":"164","author":"Birg\u00fcl","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130791_bb0160","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10895-018-2306-4","article-title":"The detailed comparison of cell death detected by Annexin V-PI counterstain using fluorescence microscope, flow cytometry and automated cell counter in mammalian and microalgae cells","volume":"28","author":"Ko\u00e7","year":"2018","journal-title":"J Fluoresc"},{"key":"10.1016\/j.bmcl.2026.130791_bb0165","doi-asserted-by":"crossref","first-page":"17446","DOI":"10.1021\/acsomega.3c00692","article-title":"Design and development of COX-II inhibitors: current scenario and future perspective","volume":"8","author":"Chahal","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmcl.2026.130791_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073659","article-title":"Evaluation of selective COX-2 inhibition and in silico study of kuwanon derivatives isolated from Morus alba","volume":"22","author":"Baek","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2026.130791_bb0175","doi-asserted-by":"crossref","first-page":"12793","DOI":"10.1074\/jbc.M114.635987","article-title":"Action at a distance: mutations of peripheral residues transform rapid reversible inhibitors to slow, tight binders of cyclooxygenase-2","volume":"290","author":"Blobaum","year":"2015","journal-title":"J Biol Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:34:33Z","timestamp":1792067673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26002581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":35,"alternative-id":["S0960894X26002581"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130791","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and preliminary in vitro screening of novel tolmetin hydrazones against colon cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130791"}}